Blood Thinner Shows Benefit
Medicines Co.'s anticlotting drug, Cangrelor, significantly outperformed the widely used medicine clopidogrel in heart patients getting stents. The results follow two earlier studies that failed to show a benefit. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 11, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Plavix Disclosures are Probed
The U.S. Justice Department is investigating disclosures to the FDA about the variability in patient responses to the blood-thinning drug Plavix, according to Sanofi, one of the drug's co-marketers. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 11, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Medicines Co's Cangrelor clearly tops Plavix in pivotal trial
SAN FRANCISCO (Reuters) - The Medicines Co's experimental intravenous blood clot preventer Cangrelor, which is intended for use during angioplasty procedures, solidly outperformed commonly used Plavix in a pivotal late stage study, likely resurrecting the drug's prospects. (Source: Reuters: Health)
Source: Reuters: Health - March 10, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Cangrelor cuts complications at PCI vs clopidogrel in CHAMPION-PHOENIX; bleeding a caution
PCI indication didn't matter: the risk of periprocedural complications like MI or stent thrombosis fell with the newer ADP-receptor blocker, given intravenously, compared with oral clopidogrel. Whether bleeding risks were similar depended on how bleeding is defined. (Source: theHeart.org)
Source: theHeart.org - March 10, 2013 Category: Cardiology Source Type: news

ACC: Novel IV Agent 'CHAMPION' Antiplatelet (CME/CE)
SAN FRANCISCO (MedPage Today) -- The novel fast-acting antiplatelet agent cangrelor given at the time of percutaneous coronary intervention (PCI) cuts ischemic complications better than clopidogrel (Plavix), the CHAMPION PHOENIX trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 10, 2013 Category: Cardiology Source Type: news

New Anti-clotting Drug More Effective than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. (Source: BWH News)
Source: BWH News - March 10, 2013 Category: Hospital Management Source Type: news

New Anti-clotting Drug More Effective than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. (Source: BWH for Journalists)
Source: BWH for Journalists - March 10, 2013 Category: Research Source Type: news

New Anti-clotting Drug More Effective than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. (Source: BWH News)
Source: BWH News - March 10, 2013 Category: Hospital Management Source Type: news

Sanofi says U.S. probing Plavix disclosures to FDA
PARIS (Reuters) - The U.S. Department of Justice (DoJ) is investigating disclosures to the Food & Drug Administration (FDA) about the variable response that certain patients may have to blood-thinner Plavix, Sanofi said in its annual report. (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Systematic review and meta-analysis of new oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome
Source: European Heart Journal Area: News Oral vitamin K antagonists have been shown to prevent recurrent ischaemic events after acute coronary syndrome (ACS), both as mono-therapy and in combination with aspirin, but substantially increase bleeding. The potential of new oral anticoagulants as antithrombotic therapy after ACSs has been investigated over the past few years and consistent increases in bleeding and the less consistent reduction in ischaemic events have been reported. The overall benefit-risk profile of adding new oral anticoagulants to antiplatelet treatment after an ACS is unknown.   This meta-anal...
Source: NeLM - Cardiovascular Medicine - March 7, 2013 Category: Cardiology Source Type: news

Tranexamic acid role in coronary bypass surgery
Tranexamic acid balances the increased bleeding risk associated with recent clopidogrel use in patients undergoing on-pump coronary artery bypass grafting, shows a randomized trial. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - March 7, 2013 Category: Cardiology Source Type: news

Aspirin plus drug reduces stroke risk
SAN FRANCISCO, Feb. 27 (UPI) -- Stroke patients or those with a transient ischemic attack who added Plavix to aspirin had less risk of second stroke, U.S. and Chinese researchers say. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 27, 2013 Category: Consumer Health News Source Type: news

Combined clopidogrel, tranexamic acid improved outcomes in CABG patients
(Source: HemOncToday.com)
Source: HemOncToday.com - February 27, 2013 Category: Cancer & Oncology Source Type: news

WOEST supports clopidogrel only in PCI patients on anticoagulation
Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy. (Source: MedWire News - Thrombosis)
Source: MedWire News - Thrombosis - February 25, 2013 Category: Internal Medicine Source Type: news

WOEST supports clopidogrel only in PCI patients on anticoagulation
Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - February 25, 2013 Category: Cardiology Source Type: news

Expert position paper on use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
Source: Eur Heart J Area: News The European Society of Cardiology NSTEMI and STEMI guidelines and an ACCF/ACG/AHA consensus document recommend treatment with proton pump inhibitors (PPIs) in patients treated with dual antiplatelet treatment (DAPT) during the initial phase of an acute coronary syndrome (ACS), particularly in patients with a history of GI bleeding or peptic ulcer. Several studies have raised concerns that many PPIs, especially omeprazole, might diminish the antiplatelet effects of clopidogrel, most likely through inhibition of CYP2C19 and, consequently, the conversion of clopidogrel into its active metaboli...
Source: NeLM - Cardiovascular Medicine - February 21, 2013 Category: Cardiology Source Type: news

Early switch from prasugrel to clopidogrel may influence outcomes
(Source: HemOncToday.com)
Source: HemOncToday.com - February 20, 2013 Category: Cancer & Oncology Source Type: news

Antiplatelet Switch Still Has Bleeding Risks (CME/CE)
(MedPage Today) -- Switching high-risk patients to clopidogrel (Plavix) can help counteract the low platelet reactivity common with prasugrel (Effient), but doing so has risks of its own, a first-of-its-kind study found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 19, 2013 Category: Cardiology Source Type: news

RCT: Clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention (WOEST)
Source: Lancet Area: News If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, double antiplatelet therapy with aspirin and clopidogrel is indicated. However, such triple therapy increases the risk of serious bleeding and this treatment strategy has not been tested prospectively.   Omission of oral anticoagulants could lead to an increased risk of thrombotic stroke, whereas clopidogrel is essential to prevent stent thrombosis. The exclusion of aspirin might, therefore, be useful to reduce the bleeding risk in patients with coronary artery disease.   The open-lab...
Source: NeLM - News - February 13, 2013 Category: Drugs & Pharmacology Source Type: news

Short course of aspirin, clopidogrel cuts stroke risk
Brief combination therapy reduces recurrent stroke over aspirin alone, without increasing bleeding risk, CHANCE trial results show. (Source: theHeart.org)
Source: theHeart.org - February 12, 2013 Category: Cardiology Source Type: news

Adding Clopidogrel to Aspirin Therapy Reduces Risk of Second Stroke
Source: American Heart Association Related MedlinePlus Pages: Blood Thinners, Stroke (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 12, 2013 Category: Consumer Health News Source Type: news

Short Course of Aspirin, Clopidogrel Cuts Stroke RiskShort Course of Aspirin, Clopidogrel Cuts Stroke Risk
Brief combination therapy reduces recurrent stroke over aspirin alone, without increasing bleeding risk, CHANCE trial results show. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Antiplatelet Duo Helps After Minor Stroke (CME/CE)
HONOLULU (MedPage Today) -- In the months immediately after a minor stroke or transient ischemic attack (TIA), adding clopidogrel to aspirin therapy cuts the risk of another stroke, a Chinese trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 10, 2013 Category: Cardiology Source Type: news

Sanofi CEO: It's Not A Plavix Hangover, We're Investing In Launching New Drugs
Sanofi, which has been one of the best-performing drug stocks over the past year, is getting hit today because the company said that earnings in 2013 will be somewhere between flat and down 5%. That's a big deal because Sanofi had previously said that 2013 would be a "trough year," the low point before it returns to growth after facing patent expirations for Plavix, once one of the biggest selling medicines in the world, and other drugs. The company reiterated its guidance out to 2015, despite pointed questions from analysts, but the stock is still trading down almost 6% on the New York Stock Exchange. (Sour...
Source: Forbes.com Healthcare News - February 7, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Science minister lobbies health department over ticagrelor
Source: BMJ Area: News According to a report in the British Medical Journal (BMJ), Government ministers are stepping up efforts to boost NHS prescriptions of recommended new drugs made by companies with a significant presence in the United Kingdom. This follows growing complaints from the drug industry that doctors are not prescribing drugs which have been recommended by NICE.   The example of ticagrelor is highlighted - this has been approved by NICE as a treatment option for adults with acute coronary syndromes but is more costly than clopidogrel (£54.60 versus £3.40 per month). AstraZeneca say that...
Source: NeLM - Cardiovascular Medicine - February 4, 2013 Category: Cardiology Source Type: news

Outsource Or Manage Internally? Pharma Logistics, 9-10 April 2013, Vienna, Austria
"The current trend in pharma logistics is the shift from blockbuster drugs. 6 out of 10 top selling drugs will lose their patents in one year, so there will be increase in the use of generic drugs," Sebastiaan Scholte, Chairman at Cool Chain Association, pointed out when speaking about the latest developments. These trends influence drug manufacturers and make them rethink their strategies. Already without medications like Lipitor and Plavix bolstering their bottom lines, manufacturers have to cut costs in order to stay competitive... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 31, 2013 Category: Consumer Health News Tags: Conferences Source Type: news

Tax Benefit Boosts Bristol's Profit
Bristol-Myers Squibb's fourth-quarter profit rose 8.6% on a tax benefit, while sales tumbled 23% due to generic competition for the company's former top product, the anti-clotting drug Plavix. (Source: WSJ.com: Health)
Source: WSJ.com: Health - January 24, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Pharmacodynamics of Prasugrel vs Clopidogrel in ElderlyPharmacodynamics of Prasugrel vs Clopidogrel in Elderly
Which therapy is best for elderly patients presenting with acute coronary syndromes? American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Blue Sky Drugs Announces Holiday Promotion on Newest Blood Thinners
Blue Sky Drugs is offering a holiday promotion on the newest blood thinner medications. Anticoagulants protect against the formation of clots.(PRWeb January 17, 2013)Read the full story at http://www.prweb.com/releases/canadianpharmacy/plavix/prweb10313064.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 18, 2013 Category: Pharmaceuticals Source Type: news

Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment
Source: Circulation: Cardiovascular Quality and Outcomes Area: Evidence> Medicines Management> References Background: In acute myocardial infarction, the relationship between volume and quality indicators (QIs) is poorly documented.  Through a nationwide assessment of QIs at discharge repeated for 3 years, we aimed to quantify the relationship between volume and QIs in survivors after acute myocardial infarction. Methods and Results: Almost all healthcare centres in France participated.  Medical records were randomly selected.  Data collection was performed by an independent group.  QIs for ac...
Source: NeLM - Cardiovascular Medicine - January 17, 2013 Category: Cardiology Source Type: news

Abuse of Opana ER (oxymorphone) associated with thrombotic thrombocytopenic purpura
3.5 out of 5 stars Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012. MMWR 2013 Jan 11;62:1-4. Full Text This paper describes a 2012  CDC investigation into a cluster of 15 cases of thrombotic thrombocytopenic purpura (TTP)-like illness in the state of Tennessee. TTP-like illness was defined as microangiopathic hemolytic anemia (hemolytic anemia anemia based on haptoglobin and lactate dehydrogenase with schistocytes and an admission platelet count 
Source: The Poison Review - January 15, 2013 Category: Toxicology Authors: Leon Tags: Medical opana oxymorphone thrombotic thrombocytopenic purpura ttp Source Type: news

Analysis of recurrent events in patients receiving ticagrelor or clopidogrel for ACS in the PLATO study
Source: Circulation Area: News According to an analysis of recurrent events in the PLATO study, ticagrelor reduces both the first and recurrent cardiovascular events in patients with acute coronary syndrome (ACS) compared with clopidogrel. Although it is associated with a slightly increased risk of having a first non-CABG major bleed, the bleeding risk appears to be similar to clopidogrel thereafter.    The authors note that censoring patients after the first occurrence of any primary endpoint event in clinical trials limits the information available on the effect of therapy on subsequent events, and leaves ...
Source: NeLM - Cardiovascular Medicine - January 14, 2013 Category: Cardiology Source Type: news

Research suggests optimal duration of dual antiplatelet therapy may vary depending on stent type
Source: Eur Heart J Area: News According to research published early online in the European Heart Journal, the optimal duration of dual antiplatelet therapy (DAPT) may differ depending on the type of stent implanted.   The authors note that this currently remains a controversial issue due to the lack of prospective, randomised data.  They conducted a pre-specified analysis of the PRODIGY study to assess device-specific outcomes relative to different duration of DAPT after everolimus- (EES), paclitaxel (PES), zotarolimus- (ZES-S) eluting, or bare metal stent (BMS) insertion.   The open-label PRODIGY ...
Source: NeLM - Cardiovascular Medicine - January 14, 2013 Category: Cardiology Source Type: news

Ticagrelor more cardioprotective than clopidogrel
NEW YORK (Reuters Health) - Ticagrelor is better than clopidogrel at reducing cardiovascular events - including recurrent events - in patients with acute coronary syndromes, researchers say. (Source: Modern Medicine)
Source: Modern Medicine - January 11, 2013 Category: Journals (General) Source Type: news

Cangrelor at PCI Cuts Ischemic Events vs ClopidogrelCangrelor at PCI Cuts Ischemic Events vs Clopidogrel
Not yet approved by regulators anywhere, the novel P2Y12-receptor antagonist reduced the risk of 48-hour ischemic events compared with the older antiplatelet. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Early Results: Antiplatelet Drug Cangrelor Superior to Clopidogrel In PCI Patients At 48 Hours
The experimental antiplatelet drug cangrelor was superior to traditional clopidogrel in reducing ischemic events at 48 hours in PCI patients, according to the Medicines Company, which is developing the drug. The company today announced positive results from the phase 3 CHAMPION PHOENIX trial, a randomized, double-blind study comparing intravenous cangrelor to oral clopidogrel in PCI patients. The primary endpoint was the composite of death, MI, revascularization and stent thrombosis at 48 hours. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 8, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Cangrelor at PCI cuts ischemic events vs clopidogrel: Preliminary phase 3 results
Not yet approved by regulators anywhere, the novel P2Y12-receptor antagonist reduced the risk of 48-hour ischemic events compared with the older antiplatelet. (Source: theHeart.org)
Source: theHeart.org - January 8, 2013 Category: Cardiology Source Type: news

Prasugrel after clopidogrel safe in acute coronary syndrome: study
NEW YORK (Reuters Health) - Prasugrel reloading after clopidogrel loading appears safe before percutaneous interventions for acute coronary syndrome (ACS), a new paper says. (Source: Modern Medicine)
Source: Modern Medicine - January 8, 2013 Category: Journals (General) Source Type: news

Fibrinogen Level Tied to Poorer PCI Outcomes (CME/CE)
(MedPage Today) -- An elevated serum fibrinogen level predicted worse short-term ischemic outcomes among patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 7, 2013 Category: Cardiology Source Type: news

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomised evaluation of long-term anticoagulation therapy (RE-LY®) trial: subgroup analysis
Source: Circulation Area: News RE-LY showed that dabigatran etexilate 150 mg bid (DE150) was superior, and 110 mg bid (DE110) non-inferior to warfarin in preventing stroke and systemic embolism (SSE) in patients with atrial fibrillation (AF). A common clinical dilemma regarding treatment of patients with AF is the need to use concomitant antiplatelets for a variety of reasons. While the combination of OAC and antiplatelets carry the potential of additive benefits, they also carry the danger of increased risk of bleeding.   With the emergence of dabigatran, questions on its efficacy and safety in patients receivin...
Source: NeLM - Cardiovascular Medicine - January 4, 2013 Category: Cardiology Source Type: news

Reduced copayment policy has benefits all round
Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say. (Source: MedWire News - Thrombosis)
Source: MedWire News - Thrombosis - October 18, 2012 Category: Internal Medicine Source Type: news

Cardiovascular Patients With a Certain Gene Mutation Respond Better to Higher Clopidogrel Doses
Current standard dosage for Clopidogrel may not be effective for individuals with a certain gene mutation that prevents the body from converting the medicine to a form it can use. (Source: BWH News)
Source: BWH News - November 16, 2011 Category: Hospital Management Source Type: news